

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 08330-0342US1	APPLICATION NO. Not Yet Known (I.A. PCT/GB2003/005163)
APPLICANT: Gillian Lindy Durrant		
FILING DATE (I.A. 26 November 2003)		GROUP Not Yet Known

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <u>YES</u> <u>NO</u>	
	A	WO 98/06838	19 Feb 1998	PCT	C12N	15/12	
	B	WO 00/37489	29 June 2000	PCT	C07K	14/00	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C	Baldwin et al., "Monoclonal Antibody 791T/36 For Tumor Detection And Therapy For Metastases", <i>Symposium On Fundamental Cancer Research</i> 36:437-455 (1983)
D	Spendlove et al., "Mapping The Binding Site Of A Novel Antibody To SCR-1 And 2 of CD55", <i>Immunology</i> 98(1): 101 (1999)
E	Bradley et al., "A Monoclonal Antibody Directed Against SCR1-2 Of Complement Control Protein, CD55 Enhances C3 Deposition And Tumor Cell Lysis", <i>British Journal Of Cancer</i> 88 (Supplement 1): S39 (2003)
F	Pimm et al., "A Bispecific Monoclonal Antibody Against Methotrexate And A Human Tumor Associated Antigen Augments Cytotoxicity Of Methotrexate-Carrier Conjugate", <i>British Journal Of Cancer</i> 61(4): 508-513 (1990)
G	Spendlove et al., "Decay Accelerating Factor (CD55): A Target For Cancer Vaccines?", <i>Cancer Research</i> 59(10): 2282-2286 (1999)
H	Hamann et al., "Characterization Of The CD55 (DAF)-Binding Site On The Seven-Span Transmembrane Receptor CD97", <i>European Journal Of Immunology</i> 28(5): 1701-1707 (1998)

EXAMINER /Maher Haddad/	DATE CONSIDERED 03/03/2009
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	